Solventum Corp.
Congress has disclosed 5 buys and 3 sells of SOLV (Solventum Corp.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying SOLV and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Alan Armstrong | 2026-03-27 | $62.76 | $82.27 | +31.1% | in profit |
| Rohit Khanna | 2026-05-01 | $66.63 | $82.27 | +23.5% | in profit |
Price as of 2026-11-02. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
how it's calculated
Legislation Related Legislation
Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
9 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rohit Khanna | House | BUY OCR ◆ insider convergence · moderate | Child | 2026-05-01 | 38 days | +18.2% | $1K–$15K | 17.8 | ↗ filing |
| Alan Armstrong | Senate | BUY ◆ insider convergence · moderate | Self | 2026-03-27 | 116 days | +25.2% | $1K–$15K | 99.1 | ↗ eFD |
| Rohit Khanna | House | SELL OCR ◆ insider divergence · moderate | Child | 2026-01-22 | 12 days | -5.6% | $1K–$15K | 28.6 | ↗ filing |
| James French Hill | House | SELL | Self · HILL 1998 TRUST | 2025-12-31 | 0 days | 0.0% | $15K–$50K 0.3% of NW |
85.3 | ↗ filing |
| Rohit Khanna | House | BUY OCR | Child | 2025-12-23 | 12 days | -1.9% | $1K–$15K | 25.1 | ↗ filing |
| Rohit Khanna | House | BUY OCR | Child | 2025-12-08 | 27 days | -4.3% | $1K–$15K | 47.4 | ↗ filing |
| Rohit Khanna | House | BUY OCR | Child | 2025-11-20 | 14 days | +7.2% | $1K–$15K | 82.1 | ↗ filing |
| Julie Johnson | House | SELL | Joint · Merrill Lynch Tax Efficient Core | 2025-01-15 | 23 days | +1.9% | $1K–$15K <0.1% of NW |
62.6 | ↗ filing |
| Thomas Tuberville | Senate | OTHER | Joint | 2024-05-03 | 824 days | — | $1K–$15K | 98.8 | ↗ eFD |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in SOLV — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in SOLV, 2 coincided with corporate insiders moving the same way within 60 days, and 1 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-03-10 | Wendell Amy McBride | Director | BUY | $100K | ↗ EDGAR |
| 2025-08-15 | 3M CO | Other | SELL | $646.4M | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| Congress | 2026-05-01 | Rohit Khanna | BUY | $1K–$15K |
| Congress | 2026-03-27 | Alan Armstrong | BUY | $1K–$15K |
| ◆ insider | 2026-03-10 | Wendell Amy McBride Director | BUY | $100K |
| Congress | 2026-01-22 | Rohit Khanna | SELL | $1K–$15K |
| Congress | 2025-12-31 | James French Hill | SELL | $15K–$50K |
| Congress | 2025-12-23 | Rohit Khanna | BUY | $1K–$15K |
| Congress | 2025-12-08 | Rohit Khanna | BUY | $1K–$15K |
| Congress | 2025-11-20 | Rohit Khanna | BUY | $1K–$15K |
| ◆ insider | 2025-08-15 | 3M CO Other | SELL | $646.4M |
| Congress | 2025-01-15 | Julie Johnson | SELL | $1K–$15K |
| Congress | 2024-05-03 | Thomas Tuberville | OTHER | $1K–$15K |
FAQ Common questions
How much has Congress traded SOLV?
5 disclosed buys and 3 sells of SOLV (Solventum Corp.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade SOLV?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.